The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment
Emergence of multi-targeted kinase inhibitors (MTIs) and immune checkpoint inhibitors (ICI) have changed the landscape of management in hepatocellular carcinoma (HCC). Combination therapy involving ICI has superseded sorafenib as the first-line treatment option for advanced HCC due to their superior...
Sparad:
| Huvudskapare: | , |
|---|---|
| Materialtyp: | Bok |
| Publicerad: |
LLC "MEDIAFORMAT",
2024-07-01T00:00:00Z.
|
| Ämnen: | |
| Länkar: | Connect to this object online. |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signum: |
A1234.567 |
|---|---|
| Exemplar 1 | Tillgänglig |